top of page
Search

The primary endpoint of these trials was symptomatic COVID-19, not hospitalization or death Dr Peter McCullough

The primary endpoint of these trials was symptomatic COVID-19, not hospitalization or death Dr Peter McCullough

McCullough’s more precise (and frequently repeated) point

McCullough and others have argued, including in Senate testimony, that:

  • The primary endpoint of these trials was symptomatic COVID-19, not hospitalization or death.

  • The trials were not powered to definitively show reductions in hospitalization or mortality as primary or key secondary endpoints (there were very few such events overall in the relatively healthy trial populations).

  • After the Emergency Use Authorizations, most placebo recipients were unblinded and offered the vaccine, ending the pure placebo-controlled follow-up for longer-term outcomes.

  • Therefore, claims that the vaccines “saved millions of lives” rely primarily on later observational studies, modeling, and post-authorization data rather than the original randomized, double-blind, placebo-controlled trials demonstrating mortality benefit.

He has stated versions of this in hearings (including discussions around myocarditis and vaccine policy) and in public statements: no placebo-controlled RCT showed a reduction in hospitalization or death as a primary/secondary endpoint in the way those hard outcomes are usually required for such claims.

__________________________________________ Substack / Focal Points (his writing/newsletter): Often linked as petermcculloughmd.substack.com or via thefocalpoints.com

 
 
bottom of page